Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450664 | 0.84 | — | — | |
| SCHEMBL28546521 | 0.82 | KMT2A (0.30) | — | |
| SCHEMBL949639 | 0.72 | — | — | |
| Ethylene Glycol SCHEMBL3631014 | 0.70 | — | — | |
| SCHEMBL6456312 | 0.70 | ALDH1A1 (0.35) | PTGER3PTGER2 | |
| Octanedioate SCHEMBL29452953 | 0.70 | ALDH1A1 (0.35) | PTGER3PTGER2 | |
| SCHEMBL8818958 | 0.70 | FABP4 (0.32) | — | |
| SCHEMBL5441572 | 0.69 | ALDH1A1 (0.35) | PTGER3PTGER2 | |
| SCHEMBL557138 | 0.67 | TSHR (0.40) | PTGER3PTGER2 | |
| SCHEMBL1943663 | 0.67 | TSHR (0.40) | PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097752-B1 | METHOD FOR THE PURIFICATION OF AT LEAST ONE TARGET SUBSTANCE THAT IS TO BE IDENTIFIED | PETER JOCHEN (DE) | 2011-05-18 | — | — | EP | claimed |
| EP-2097752-A2 | METHOD FOR THE PURIFICATION OF AT LEAST ONE TARGET SUBSTANCE THAT IS TO BE IDENTIFIED | Peter, Jochen (DE) | 2009-09-09 | — | — | EP | claimed |
| WO-2008055671-A2 | METHOD FOR THE PURIFICATION OF AT LEAST ONE TARGET SUBSTANCE THAT IS TO BE IDENTIFIED | STEINBEIS GMBH & CO KG FUER TE (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-0882448-B1 | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor | DIDECO SRL (IT) | 2005-01-12 | — | — | EP | claimed |
| EP-0856055-A1 | STREPTAVIDIN MUTANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-08-05 | — | — | EP | claimed |
| WO-1997011183-A1 | STREPTAVIDIN MUTANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-03-27 | — | — | WO | claimed |
| US-20220306710-A1 | TREATING ALZHEIMER'S DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| EP-4061396-A1 | TREATING ALZHEIMER'S DISEASE | Yeda Research and Development Co. Ltd (IL) | 2022-09-28 | — | — | EP | disclosed |
| US-20200384130-A1 | B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED NANOPARTICLES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-10 | — | — | US | disclosed |
| EP-3638319-A1 | B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED NANOPARTICLES | Dana-Farber Cancer Institute, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-106170564-B | Proximity assays based on detection of Hybrid Chain Reaction (HCR) | 欧凌科生物科技公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2018231949-A1 | B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED NANOPARTICLES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| CN-105452466-A | Aptamers and uses thereof | CARIS LIFE SCIENCES SWITZERLAND HOLDINGS S A R L | 2016-03-30 | — | — | CN | disclosed |
| EP-1316594-A1 | Silane group containing polymers | Bayer Aktiengesellschaft (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | CONJUCHEM, INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| US-20020009441-A1 | Reactively modified therapeutic compounds having an extended lifetime in vivo | POULETTY PHILIPPE (US) | 2002-01-24 | — | — | US | disclosed |
| US-6022951-A | MODIFIED ANTIBIOTIC PEPTIDE FOR INCREASED OR DECREASED SENSITIVITY TO BIOTIN, AND METHODS FOR UTILIZING THESE PROTEINS IN DETECTION, ISOLATION AND PURIFICATION TECHNIQUES | U.S. DEPARTMENT OF ENERGY | 2000-02-08 | — | — | US | disclosed |
| EP-0856055-A1 | STREPTAVIDIN MUTANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997011183-A1 | STREPTAVIDIN MUTANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0304934-A2 | Labelled molecular probes, their production and use | Hunger, Hans-Dieter (DE) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | FABP3, VCAM1, TAGLN2 | PTGER4 4021/4885PTGER3 3493/4885PTGER2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.